Roche 's $1.4 billion deal to buy Igen International Inc. [See Deal] left Igen shareholders gleeful to say the least and some Roche observers a bit wary of the high price tag and generous terms. But by ending protracted litigation between the two companies, the deal protects one of Roche Diagnostics ' core franchises, its centralized laboratory business.
The purchase also underscores Roche's willingness to pay dearly for coveted technology that will lead to leadership in an important market. In some cases, as with the acquisition of polymerase...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?